View our currently open positions.

Job listings brought to you by Rippling ATS.
Announcing the $15M Catalytic Fund. Together we can reach 5M mothers and babies by 2025!

Our Impact

Our medical products help increase maternal and newborn survival rates, improve mobility, and scale world-class, affordable solutions across more than 70 countries. But don't just take our word for it, see what the numbers say.


*updated quarterly

  • 1,407,000

    patients treated with our products

  • 1,024,000

    disability-adjusted life years (DALYs) averted

  • 1,210,000

    Patients who otherwise would not have received effective treatment

  • 3,211

    healthcare workers trained by our
    ECHO Telementoring

  • 429,000

    patients treated by our

    ECHO-trained clinicians

  • Latest impact audit
How we measure impact

We go beyond counting the number of products sold or workshops run. We track the number of units installed, where they are installed, how they are being used, and keep our focus on health outcomes.

Download our annual report
Equalize Health
Partners

We are one of the world’s most effective charities. We deliver the most impact for the least money. It’s one of the reasons why we are funded and recommended by the world’s most discerning philanthropic organizations.

What makes us so effective?
  • Nimble. Our global team can move fast and get great results on modest budgets.

  • Not-for-profit status. We attract more diverse funding streams and invest in more socially impactful projects than commercial medical companies.

  • Scalable. Public and private partnerships ensure our products get to market and into the hands of people who need them most.

  • Impact-driven We rigorously measure our impact, including through third-party evaluations.

  • Market-driven. We use the market and aim to drive competition, resulting in lower prices, higher quality and interest from other med tech companies.

Independent evaluation of our work.

We actively seek independent, third party monitoring and evaluation.